Group items tagged

Bas Vorsteveld has been elected as the new president of PAGB, the trade association representing the manufacturers of branded OTC medicines, self care medical devices and food supplements. Vorsteveld, who is vice president and general Manager of Haleon GB and Ireland, succeeds Neil Lister, managing director UK & Ireland and vice president at Perrigo. PAGB said the appointment comes at a crucial time for the consumer healthcare association as it looks to expand the role of self-care, secure a long-term favourable business environment for members, adapt to environmental challenges and continue to deliver excellent services for members. "We are so pleased to welcome Bas to the role of President. Bas has been actively involved with PAGB as a board member and we're looking forward to continuing our work with him. I have already seen from Bas's time on our Board that he combines great sector knowledge with drive, energy and genuine passion for what we do and we're so excited to have him as our President," Michelle Riddalls, chief executive of PAGB, said. "Bas's input and guidance as our strategy evolves over the coming years will be vital as we respond to new challenges as they emerge and make the most of the opportunities ahead."

The Galien Foundation recently announced the winners of the 2024 Prix Galien UK Awards, with the University of Oxford receiving accolades for its groundbreaking contributions to public sector innovation through the PRINCIPLE and PANORAMIC Trials. These trials, spearheaded by Oxford's team of experts, have set a new standard for scientific innovation aimed at improving global health outcomes. Led by University of Oxford, the PRINCIPLE and PANORAMIC Trials epitomize a remarkable collaboration aimed at combating the COVID-19 pandemic.

Walgreens Boots Alliance (WBA) has officially announced that Sebastian James, the Managing Director of Boots, will be stepping down from his role to pursue a new opportunity in the healthcare sector. James has given notice to leave the company and will remain with Boots until November. The UK pharmacy giant has already begun the search for a new Managing Director. James is set to take on the role of CEO at Veonet, a leading European chain of ophthalmology clinics. During his tenure as Managing Director since 2018, James played a pivotal role in transforming Boots into the UK's leading health and beauty retailer. He oversaw significant growth and innovation, achieving thirteen consecutive quarters of retail market share growth. Most recently, the company announced strong Q3 results in June with growth across all categories.

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and recycling initiative. NHS Trusts and community pharmacies participating in the new scheme will have specialised recycling containers for inhalers installed to simplify public participation, Grundon said in a statement. Inhalers alone contribute to 4 per cent of NHS CO2 emissions, with around 73 million dispensed annually. By 2026, the health service aims to achieve a 50 per cent reduction in carbon emissions from waste management, a target that rises to 80 percent between 2028 and 2032, as outlined in the NHS Clinical Waste Strategy. "This scheme holds the potential to revolutionise the approach of NHS Trusts towards achieving heightened carbon savings and ultimately, net zero emissions," said Chris Edwards, Grundon's General Manager - Technical. "Each discarded pressurised Metered Dose Inhaler (pMDI) contains highly polluting hydrofluorocarbon (HFC) gases - a category of greenhouse gas known to be over a thousand times more detrimental than carbon dioxide in driving climate change." "This initiative securely captures these gases and repurposes them for application in the refrigeration sector. By also recycling the plastic and aluminium components of the device, we are making a noteworthy contribution to the circular economy," he added. Once collected, these will undergo processing at Grundon's specialist recycling facility in Ewelme, Oxfordshire, which is capable of handling more than 200,000 inhalers a day. The company aims to recycle 80 per cent of all prescribed inhalers by 2025, the statement added.

The Pharmacists' Defence Association (PDA) has advised locums that they are under "no direct obligation" to help contractors gather data for an HM Revenue and Customs (HMRC) investigation. However, they may choose to assist the large contractors "to help ensure HMRC reach a final decision based on all the relevant facts," PDA said. The HMRC investigation into the tax status of locums forms part of the extension of the IR35 arrangements into the private sector. The IR35 came into effect from April to ensure that individuals working like employees through their own limited company pay the same income tax as paid by those employed by a company. In recent weeks, some contractors have contacted locum pharmacists to assist them in data gathering on their work arrangements.

The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations. A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023. Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway. "We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."

Darren Jones MP, the Shadow Chief Secretary to the Treasury, visited Sigma Pharmaceuticals plc's new Watford facility on Thursday (6 June) as part of the imminent Labour Party campaign trail. Jones was joined by Labour's prospective parliamentary candidate for Watford, Matt Turmaine, and a team of campaign workers. During their visit, the Labour delegation met with the directors and founding member of Sigma, Dr Bharat Shah CBE, and discussed the importance of investment and support for growing businesses and the pharmaceutical sector both in the region and across the country. Sigma Pharmaceuticals, which is believed to be Watford's largest employer, noted that the pharmaceutical sector contributes a significant value to the East of England, accounting for 12.3 per cent of the region's manufacturing gross value added (GVA).

The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for branded medicines pricing on Thursday (4 May). A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023 In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth. Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities. The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life sciences sector.

Over the last few years, we've seen the aftermath of Covid-19, with the demand for consumer health products being unprecedented and unpredictable, placing pressure on supply chains and labour market. In turn, the industry has experienced acute shortages across the healthcare sector, placing huge pressure on pharmacists, doctors, nurses, and other healthcare professionals. Europe has an estimated shortage of around 50,000 public-sector doctors[1], which is set to increase in the coming years. While this shortage stems from several complex problems, there is a hidden force that could play a key part in helping to alleviate this burden. That force is the potential of self-care. Encouragingly, last month the UK government recognised the unique role that self-care can play through the introduction of its Delivery plan for recovering access to primary care. Through this, it has pledged to empower patients to manage their own health through several commitments, including improving accessibility to online tools and reclassifying medicines to make formerly prescribed options available over the counter.

At the Future of Britain Conference 2024, the newly appointed Secretary of Health and Social Care, (DHSC) Wes Streeting, stated that "Labour's DNA is in the NHS". He also called for a long-term approach to reform the broken health sector and the integration of artificial intelligence (AI) to steer the healthcare system towards sustainability and growth. Hosted by Tony Blair Institute for Global Change and My Life My Say today, Tuesday, 9, Streeting discussed the plans to fix the healthcare system and role of Artificial Intelligence (AI) in "making the right choices" by bringing in three essential shifts in the healthcare. Criticising the previous Conservative administration for leaving "massive burning deck issues" due to constant reshuffling within the Department of Health and Social Care (DHSC), Streeting lamented that this "instability" and "indecisions" have made comprehensive reform even more pressing. Drawing inspiration from Chancellor Rachel Reeves' speech on economic growth, Streeting stressed the interconnectedness of health and economic prosperity.

Following centuries of stigma, the importance of mental wellness is finally matching that of physical healthcare. Conditions such as depression have become common topics in the media, particularly in the last few years as celebrities and experts warned against the pressures of social media. The bouts of isolation connected with the Covid-19 pandemic exacerbated the issue, with the British Medical Association declaring a UK mental health crisis at the end of 2022. This media attention has led to acknowledgement of the realities of mental health problems from the government and medical sector, and a recognition that these need to be approached differently to physical ailments when it comes to providing treatment. If you are motivated to be involved in this rapidly changing industry, consider these rewarding business ideas for developing a career in mental health. Become a counsellor Counselling is a broad term, but essentially it is the practice of having impartial conversation with patients about their life experiences with a view to overcoming emotional obstacles and trauma. Training can take three to five years depending on whether you are getting a degree or diploma, and there are many opportunities to specialise both during and after your education. Psychotherapy is a similar field, but this is a more academically focused course that tends to be concerned with long-term or particularly complex mental health issues. You will need a post-graduate qualification and several years of training to become certified.

Proposed changes to a European Union pharmaceuticals law will include stronger obligations for the supply of medicines and earlier notifications of shortages, EU Health Commissioner Stella Kyriakides said last week (January 17). Kyriakides told a session of the European Parliament that shortages of antibiotics are a growing problem for many European countries. She said the European Commission's proposal to revise the pharmaceuticals legislation is planned for March. "Our objective is and remains to secure access to medicines for all patients in need and to avoid any market disruption of medicines in the EU," Kyriakides said. Shortages of antibiotics have been reported in 26 European countries, the European Medicines Agency says. The unseasonably early upsurge in respiratory infections in Europe this winter and insufficient production capacity are the root causes of the shortages, Kyriakides said. Numerous EU lawmakers speaking at the session said the shortages needed to be tackled urgently. But experts say shortages of essential generic medicines like antibiotics are likely to be recurrent in Europe due to problems in the sector such as the gradual migration of generic manufacturing to Asia.

"Patients deserve choice, but wherever they go they will find vacant nursing posts and overstretched services," responded Professor Pat Cullen, RCN General Secretary and Chief Executive, to the introduction of the new pilot scheme for out-of-hospital patient care. The NHSE and the DHSC have announced a new pilot scheme commencing in autumn "offering patients a choice of where they receive out-of-hospital care". Under the initiative, individuals requiring treatment outside of hospitals will have the opportunity to select from a range of providers across both the NHS and the independent sector. Patients can select their care provider for in-hospital consultant-led services post-GP consultation, offering a choice from at least 5 providers with details on waiting times, distance, and quality.

As the general election campaign continues, Labour is set to introduce a series of policies aimed at supporting small businesses. On Saturday, Sir Keir Starmer, alongside shadow chancellor Rachel Reeves and other shadow cabinet ministers, is expected to unveil the party's plans for the sector. Key proposals include an overhaul of the business rates system to enable high street shops to compete with online giants and ensure access to high street banking services by accelerating the establishment of banking hubs. Labour will also commit to addressing the issue of late payment of invoices by requiring large businesses to disclose their payment practices and "revitalise" high streets by tackling antisocial behaviour. Sir Keir described small businesses as "the beating heart of driving growth and creating jobs for local people."

The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years, the British Generic Manufacturers Association has revealed in its new study. The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years. The BGMA research found that more than 85 biological medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028. "This includes blockbuster products like the cancer medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma." While biological medicines dominate the medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of the VPAS Scheme".

The University of Oxford's Centre for Research Equity (CfRE) has entered into a historic partnership with the Health and Social Care Research and Development (HSC R&D) Division in Northern Ireland to advance health equity across the region and ensure everyone benefits from healthcare advancements. Unveiled during an event at Parliament Buildings in Stormont Estate on Wednesday, this groundbreaking partnership makes Northern Ireland the first UK region to partner with CfRE. Supported by the Department of Health Northern Ireland and key health and social care agencies, the partnership aims to improve health outcomes and reduce disparities through collaborative research. Northern Ireland's Health Minister, Mike Nesbitt, highlighted that this new partnership represents "a significant step forward in efforts to address health inequalities" in the region. "By bringing together leading experts and resources from across sectors, we can work towards conducting research that truly benefits all of our communities," he said.

The Royal College of Nursing (RCN) has expressed "extreme disappointment" that the UK government offered new pay to NHS consultants, while nursing pay deal remain disputed. RCN General Secretary and Chief Executive Pat Cullen has written to new Health Secretary Victoria Atkins demanding fresh negotiations regarding this year's pay deal, and requested an urgent meeting to discuss their dispute. Pat warned that more than 100,000 RCN members in England voted for continued strike action in June, as they feel undervalued. "The government has now shown it has the political will to negotiate on pay reform for some of the highest earners in the NHS in contrast to our members who received the lowest pay rise in the public sector," she wrote in the letter. NHS nursing staff in England was awarded a five per cent pay rise 2023/24, but the union argued that it is not enough to keep up with inflation.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

A new Attention-Deficit-Hyperactive disorder (ADHD) taskforce has been launched by National Health Services England (NHSE) to counter the challenges faced by many suffering from the neurodevelopmental condition. The ADHD taskforce aligns with the NHS Long Term Plan's vision to revolutionise mental health services, with a specific emphasis on bolstering community-based care and reducing reliance on inpatient services. The NHS has partnered with the government to tackle the escalating demands including increasing funding, improving system efficiency, altering the service provision model, and clinical prioritisation by bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to help provide a joined-up approach in response to concerns around rising demand. Over the past two decades, there has been a significant expansion in the acknowledgement and successful medical interventions for ADHD, leading to a steady rise in clinical requests throughout the UK.

Being able to access high-quality healthcare at the times you need it most is vital. Regardless of whether this is a simple check-up, a medical review or complex surgery, having a suitable healthcare package designed according to your medical needs will be beneficial in the long run. The NHS has recently come under significant strain. Factors such as an increase in the number of patients, reduced funding and increased life expectancy have led to long waiting times and limited treatments. As a result, more individuals are now seeking private healthcare which, while it may be more expensive, offers faster and more effective treatment. Here we'll discuss some of the main benefits of private healthcare and why it is becoming the ideal choice for healthcare in 2023. Reduced waiting times One of the main issues faced by the NHS is waiting times, with some patients being made to wait up to a year for routine hospital care. Currently, ambulance services and A&E units are under unprecedented pressure and it is estimated that hundreds of deaths each week are associated with admission delays. Understaffing has been a chronic issue in recent years in the NHS and is a major threat to the welfare of patients. This has been one of the major concerns that has led to nurses and ambulance staff taking strike action. As nurses and hospital workers are put under higher strain, they are more likely to make mistakes, which could well lead to patients coming into harm and making a claim. Opting for private healthcare guarantees that you are able to access your appointments, surgeries and treatments much quicker, with some flexibility offered to align with your lifestyle. The capacity to bypass the painfully long waiting times ensures you receive the necessary medical attention much sooner and could prevent the emergence of other health complications.